Brief: Destiny Pharma Says Positive Results From XF-73 Dermal Safety Study

Destiny Pharma

31/01/2024 07:41

Jan 31 (Reuters) - Destiny Pharma PLC  DEST.L :
    * DESTINY PHARMA PLC  - CLINICAL DEVELOPMENT UPDATE
    * DESTINY PHARMA PLC - POSITIVE RESULTS FROM XF-73 DERMAL
SAFETY
STUDY
    * DESTINY PHARMA - XF-73 DERMAL TO BE PROGRESSED TOWARDS
CLINICAL
EVALUATION FOR TREATMENT OF DIABETIC FOOT INFECTIONS AND SERIOUS
BURN WOUND INFECTIONS
    * DESTINY PHARMA PLC - PRODUCT WAS WELL TOLERATED WITH NO
SIGNIFICANT IMPACT ON ANY CLINICAL OR SAFETY PARAMETERS
    * DESTINY PHARMA PLC -  PRODUCT HAD NO APPARENT NEGATIVE
IMPACT ON
WOUND HEALING

Source text for Eikon:  ID:nRSe4371Ba 
Further company coverage:  DEST.L 

 ((Reuters.Briefs@thomsonreuters.com;))